Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early-stage and emerging growth companies in the life sciences sector. The firm focuses on innovative therapeutic products, diagnostic tests, and medical devices, supporting companies from the development phase to market entry.

Ysios Capital

Ysios Capital, a leading Spanish venture capital firm, provides private equity financing to early and mid-stage life science companies that develop disruptive therapeutic products and platform technologies. Founded in 2008, Ysios Capital manages over USD 420M through three dedicated funds in life sciences and is led by a team of professionals experienced in building biotech companies.

BioVex

Aura Biosciences

STAT-Dx

TiGenix

SANIFIT

Prexton Therapeutics

Galecto

Kala Pharmaceuticals

Lava Therapeutics

Mineralys Therapeutics

Minoryx Therapeutics

CVRx

Endosense

#investment I We're proud to share that we have joined a €57M Series A round in Kynexis together with Forbion and Sunstone Life Science Ventures.

🎯 Potential first-in-class #treatment for #cognitiveimpairment associated with #Schizophrenia 

💼 Raúl Martín-Ruiz will be joining the company's Board of Directors.

🔬 The candidate, KYN-5356, is a potent and highly selective KAT-II inhibitor licensed from Mitsubishi Tanabe Pharma Corporation (MTPC). #Funds to advance KYN-5356 toward #clinical development.

The company, co-founded by Forbion and Ysios Capital, has assembled an accomplished leadership #team with decades of experience in #drugdiscovery and development for #neuropsychiatric indications

#vc #biotech ##innovation #mentalhealth #impactinvesting #braindisease

https://lnkd.in/dP4BPh-w

#portfolionews I We're thrilled to share that our #portfolio company in.bio.motion has expanded commercialization of MAF-TEST® to #Africa 👇 

 🤝 Inbiomotion and The Scientific Group sign an exclusive distribution agreement of MAF Test® for the #SubSaharan #Africa

🎯Thanks to this agreement, MAF Test® will now be available in Sub-Saharan Africa and, considering just South Africa, it could increase the survival of 8 out of 10 of the 10,200 early-stage #breastcancer patients diagnosed each year.

👩‍🔬 The MAF-TEST® #predicts the #prognosis of breast cancer patients and helps oncologists to #identify those patients who may be able to #prevent #recurrence and benefit from #adjuvant treatment with #bisphosphonates, which are commonly used to treat osteoporosis. The test also identifies those patients whose prognosis would worsen if treated with bisphosphonates.

#oncology #innovation #vc 
 
https://lnkd.in/dENxSGht

🏆#LifestarsAwards I Congrats CorWave for being named ⭐#Medtech of the year⭐ by the jury of the European Lifestars Awards - Celebrating Life Science eXecutives & their partners

🎯 Developing innovative implantable #blood #pumps based on a #breakthrough membrane technology.
 
#LifestarsAwards #Medtech #LVAD  #vc #ysiosportfolio

#portfolionews I  📌 Excellent news for our #portfolio company in.bio.motion currently commercializing its proprietary MAF-TEST®, a novel tool, backed by level 1B clinical evidence, with the potential to guide #bisphosphonate use in adjuvant breast cancer

 🔝 A team from IRB Barcelona Barcelona led by ICREA researcher Dr. Roger Gomis, co-founder of in.bio.motion, has revealed the mechanism by which the #MAF protein increases the risk of #metastasis in #breastcancer patients. This finding is a crucial step in understanding the molecular basis of metastasis and has relevant clinical implications for treatment.

🔬 The MAF protein interacts with the estrogen receptor, alters its function, and promotes the spread of cancer.

🎯 Results open the possibility of an additional clinical utility of MAF Test®.

🗣 “This study opens the possibility of preventing metastasis by preventing the activation of pro-metastatic genes. This offers new perspectives in the treatment of breast cancer and the clinical utility of MAF-TEST® could be extended to select high-risk patients for extended hormonal therapy and for selecting patients to be included in clinical trials to test the use of new class of drugs -SERDs- in the adjuvant setting as is being carried out by various global pharmaceutical companies.” said Roger Gomis

📑 Full publication here - https://lnkd.in/eDVyFwpU

#MAFTest #oncology #breastcancer #innovation #vc #ysiosportfolio #Spain #Bioregion

https://lnkd.in/dcnY6pYw

COM:YSIOSCAPITAL

Ysios Capital